Bristol Myers Squibb today announced Week 52 data from the pivotal Phase 3 POETYK PsA-1 trial further confirming the efficacy and safety of Sotyktu (deucravacitinib) in adults with active psoriatic ...
Communities across the Corn Belt are confronting a rise in cancers among young adults — and few clear explanations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback